Towards the end of 2021, SARS-CoV-2 vaccine effectiveness was threatened by the
emergence of the omicron clade (B. 1.1. 529), with more than 30 mutations in the spike …

(A) Differences from BA. 2 in BA. 2.75 (orange), and BA. 2.75. 2 (red, underlined), depicted
upon the SARS-CoV-2 BA. 2 receptor binding domain (pdb: 7UB0). Sensitivity of SARS-CoV …

Summary Background The SARS-CoV-2 omicron (B. 1.1. 529) variant, which was first
identified in November, 2021, spread rapidly in many countries, with a spike protein highly …

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
vaccinations targeting the spike protein (S) offer protective immunity against coronavirus …

The human immunoglobulin heavy-chain (IGH) locus is exceptionally polymorphic, with high
levels of allelic and structural variation. Thus, germline IGH genotypes are personal, which …

Background Licensed vaccines against SARS-CoV-2 effectively protect against severe
disease, but display incomplete protection against virus transmission. Mucosal vaccines …

Current parenteral coronavirus disease 2019 (Covid-19) vaccines inadequately protect
against infection of the upper respiratory tract. Additionally, antibodies generated by wild …

The continued evolution of SARS-CoV-2 underscores the need to understand qualitative
aspects of the humoral immune response elicited by spike immunization. Here, we combine …

Patients with COVID-19 frequently manifest adipose atrophy, weight loss and cachexia,
which significantly contribute to poor quality of life and mortality,. Browning of white adipose …

The SARS-CoV-2 Omicron Variant of Concern (B. 1.1. 529) has spread rapidly in many
countries. With a spike that is highly diverged from that of the pandemic founder, it escapes …